EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report

Shi Hyun Kim, Suyog Jain, Joo Sung Shim, Byoung Chul Cho, Sun Min Lim

Yonsei Medical Journal · 2026 · 67

DOI: 10.3349/ymj.2026.0203 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Yonsei Medical Journal, 2026. Verfasst von Shi Hyun Kim und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kim, S. H., Jain, S., Shim, J. S., Cho, B. C., & Lim, S. M. (2026). Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report. Yonsei Medical Journal, 67. https://doi.org/10.3349/ymj.2026.0203

Vancouver

Kim SH, Jain S, Shim JS, Cho BC, Lim SM. Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report. Yonsei Medical Journal. 2026;67. doi:10.3349/ymj.2026.0203

BibTeX
@article{Kim2026,
  author = {Kim, Shi Hyun and Jain, Suyog and Shim, Joo Sung and Cho, Byoung Chul and Lim, Sun Min},
  title = {Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report},
  journal = {Yonsei Medical Journal},
  year = {2026},
  volume = {67},
  doi = {10.3349/ymj.2026.0203}
}
Kostenlos starten →